Pfizer and BioNTech have launched a clinical trial on a vaccine targeting both COVID-19 and influenza, the companies announced Thursday.
In this Sept. 8, 2022, file photo, a teenager receives the Pfizer-BioNTech COVID-19 booster vaccine targeting BA.4 and BA.5 Omicron sub variants at Skippack Pharmacy in Schwenksville, Penn.Pfizer and BioNTech have launched a clinical trial on a vaccine targeting both COVID-19 and influenza, the companiesThe phase 1 trial is being done in the United States with 180 participants between the ages of 18 and 64, with the first participant dosed this week, the companies said.
The combination vaccine is based on the currently available bivalent COVID-19 booster and a quadrivalent mRNA flu vaccine, which is designed to protect against four different flu viruses. In this Sept. 9, 2022, file photo, a man gets an influenza vaccine from a pharmacist during an event hosted by the Chicago Department of Public Health at the Southwest Senior Center in Chicago.Studies indicate COVID-19 vaccine efficacy fades over time, though it's not clear if every American will need an annual COVID-19 booster.
United States Latest News, United States Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Pfizer and BioNTech creating combined flu, COVID vaccineThe companies said that 180 U.S. adults ages 18-64 are part of the Phase 1 study. It administered the first dose of the combined vaccine this week.
Read more »
Pfizer, BioNTech start COVID-flu combination vaccine studyU.S. drugmaker Pfizer Inc and its German partner BioNTech SE have started an early-stage study to evaluate a combination vaccine targeting COVID-19 and influenza, the companies said on Thursday.
Read more »
Pfizer-BioNTech testing combination flu-COVID-19 vaccineThe WHO estimates 290,000 to 650,000 people worldwide die of flu-related causes every year. About 1.1 million people in the U.S. have died from COVID-19.
Read more »
New RSV vaccine given in pregnancy protects newborns from illness, Pfizer saysThe drugmaker Pfizer announced positive trial results for its RSV vaccine designed to protect newborns.
Read more »